

BIBLIOGRAFIA RECOMENDADA

1.O profissional da saúde: estresse X motivação

- Akroyd D, Caison A, Adams RD. Burnout in radiation therapists: the predictive value of selected stressors. *Int J Radiat Oncol Biol Phys*. 2002 Mar 1;52(3):816-21.
- Albanesi de Nasetta S. Burnout en guardias médicas. *Alcmeón (Impr.)*; 11(3): 244-252, jul. 2004. Argentero P, Dell'Olivo B, Ferretti MS. Staff burnout and patient satisfaction with the quality of dialysis care. *Am J Kidney Dis*. 2008 Jan;51(1):80-92.
- Barbier D. [The burnout syndrome of the caregiver] . *Presse Med*. 2004 Mar; 33(6):394-9.
- Bressi C, Manenti S, Porcellana M, Cevalles D, Farina L, Felicioni I, et al. Haemato-oncology and burnout: an Italian survey. *Br J Cancer*. 2008 Mar 25;98(6):1046-52.
- Brown S, Gunderman RB. Viewpoint: enhancing the professional fulfillment of physicians. *Acad Med*. 2006 Jun; 81(6): 577-82.
- Cashavelly BJ, Donelan K, Binda KD, Mailhot JR, Clair-Hayes KA, Maramaldi P. The forgotten team member: meeting the needs of oncology support staff. *Oncologist*. 2008 May; 13(5):530-8.
- Courtial JP, Huteau S. [Nurses experiencing burn out in psychiatry: from research to the hospital setting] . *Sante Publique*. 2005 Sep; 17(3): 385-402.
- Crozier S. Don't burn out ... blaze new trails! . *CDS Rev*. 2001 May-Jun ;94(4): 14-8.
- Ferrer R. Burn out o síndrome de desgaste profesional. *Med Clin (Barc)*. oct. 2002;119(13): 495-6.
- Flórez Lozano JA. El síndrome de burn out en médicos y enfermeras que atienden a pacientes oncológicos: el hospital como sistema desmotivacional (y II) . *Med. integral*. 2001; 37(1): 38-47.
- Girgis A, Hansen V, Goldstein D. Are Australian oncology health professionals burning out? A view from the trenches. *Eur J Cancer*. 2009 Feb;45(3):393-9.
- Glasberg J, Horiuti L, Novais MA, Canavezzi AZ, da Costa Miranda V, Chicoli FA, Gonçalves MS, Bensi CG, del Giglio A. Prevalence of the burnout syndrome among Brazilian medical oncologists. *Rev Assoc Med Bras*. 2007 Jan-Feb;53(1):85-9.
- Grosch WN, Olsen DC. Clergy burnout: an integrative approach. *J Clin Psychol*. 2000 May; 56(5): 619-32.
- Grunfeld E, Whelan TJ, Zitzelsberger L, Willan AR, Montesanto B, Evans WK. Cancer care workers in Ontario: prevalence of burnout, job stress and job satisfaction. *CMAJ*. 2000 Jul 25;163(2):166-9.
- Heumann G, Mazzella L, Wolfberg E. Los grupos de reflexión en la labor preventiva. *Claves psicoanal. med*. 2000; 10(17/18):73-7.
- Italia S, Favara-Scacco C, Di Cataldo A, Russo G. Evaluation and art therapy treatment of the burnout syndrome in oncology units. *Psychooncology*. 2008 Jul;17(7):676-80.
- Jablkowska K, Borkowska A. [Evaluation of the intensity of stress at work and burnout syndrome in the managers]. *Med Pr*. 2005; 56(6): 439-44.
- Kash KM, Holland JC, Breitbart W, Berenson S, Dougherty J, Ouellette-Kobasa S, Lesko L. Stress and burnout in oncology. *Oncology (Williston Park)*. 2000 Nov;14(11):1621-33; discussion 1633-4, 1636-7.
- Levin R. Employee incentive programs. *J Am Dent Assoc*; 2004 May;135(5): 635-6.

- Nohria N, Groysberg B, Lee LE. Employee motivation: a powerful new model. *Harv Bus Rev.* 2008 Jul-Aug ;86(7-8): 78-84, 160.
- Nordam A, Torjuul K, Sorlie V. Ethical challenges in the care of older people and risk of being burned out among male nurses. *J Clin Nurs*; 2005 Nov ;14(10): 1248-56.
- O'Dowd TC. To burn out or to rust out in general practice. *J R Coll Gen Pract*; 37(300): 290-1, 1987 Jul. Papadatou D, Anagnostopoulos F, Monos D. Factors contributing to the development of burnout in oncology nursing. *Br J Med Psychol.* 1994 Jun;67 (Pt 2):187-99.
- Pedreño Aznar MA. Riesgo y afrontamiento del burnout de la enfermera de Salud Mental/ Risk and management of burnout syndrome in mental health Nursing .*Metas enferm.* nov. 2005; 8(9): 14-7.
- Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ Jr. Burnout: caring for the caregivers. *Oncologist.* 2000;5(5):425-34.
- Ramirez AJ, Graham J, Richards MA, Cull A, Gregory WM, Leaning MS, Snashall DC, Timothy AR. Burnout and psychiatric disorder among cancer clinicians. *Br J Cancer.* 1995 Jun;71(6):1263-9.
- Rossi LA, Camargo C, Santos CM, Barruffin R de C, de Carvalho EC. [The pain of burns: terrible for him who feels it, stressful for those who care for him] .*Rev Lat Am Enfermagem.* 2000 Jul ;8(3): 18-26. Português
- Sarata BP, Behrman J. Group home parenting: an examination of the role. *Community Ment Health J.* 1982;18(4): 274-85.
- Schraub S, Marx E. [Burn out syndrome in oncology] .*Bull Cancer.* 2004 Sep.;91(9): 673-6.
- Sherman AC, Edwards D, Simonton S, Mehta P. Caregiver stress and burnout in an oncology unit. *Palliat Support Care.* 2006 Mar;4(1):65-80. Review.
- Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abrão MN, Diniz RW, et al. Burnout in cancer professionals: a systematic review and meta-analysis. *Eur J Cancer Care (Engl).* 2008 Nov;17(6):524-31. Review.
- van Servellen G, Leake B. Burn-out in hospital nurses: a comparison of acquired immunodeficiency syndrome, oncology, general medical, and intensive care unit nurse samples. *J Prof Nurs.* 1993 May-Jun;9(3):169-77.
- Willis-Shattuck M, Bidwell P, Thomas S, Wyness L, Blaauw D, Ditlopo P. Motivation and retention of health workers in developing countries: a systematic review. *BMC Health Serv Res.* 2008;8: 247.
- Young CM, Albert NM, Paschke SM, Meyer KH. The 'Parent Shift' program: incentives for nurses, rewards for nursing teams. *Nurs Econ*; 2007; 25(6): 339-44.

2. O Processo de Acreditação Hospitalar em Oncologia

Visão do Farmacêutico. Visão do Enfermeiro. Visão do Médico

- ANVISA - Agência Nacional de Vigilância Sanitária .Resolução RDC no. 12, de 26 de janeiro de 2004. Aprova o Manual Brasileiro de Acreditação de Organizações Prestadoras de Serviços Hospitalares - 4ª Edição. D.O.U. - Diário Oficial da União; Poder Executivo, de 27 de janeiro de 2004.
- ANVISA - Agência Nacional de Vigilância Sanitária .Resolução RDC no. 245, de 15 de setembro de 2003. Aprova Manual Brasileiro de Acreditação de Organizações Prestadoras de Serviços de Laboratório Clínico. D.O.U. - Diário Oficial da União; Poder Executivo, de 16 de setembro de 2003
- ANVISA - Agência Nacional de Vigilância Sanitária .Resolução RDC No. 75, de 07 de abril de 2003. Aprova o Manual Brasileiro de Acreditação de Organizações Prestadoras de Serviços de Hemoterapia. D.O.U. - Diário Oficial da União; Poder Executivo, de 08 de abril de 2003

- ANVISA - Agência Nacional de Vigilância Sanitária. Resolução RDC no. 93, de 26 de maio de 2006. Dispõe sobre o Manual Brasileiro de Acreditação de Organizações Prestadoras de Serviços de Saúde e as Normas para o Processo de Avaliação. D.O.U. - Diário Oficial da União; Poder Executivo, de 29 de maio de 2006.
- BRASIL. Ministério da Saúde. Secretaria de Assistência à Saúde. Departamento de Sistemas e Redes Assistenciais. Manual Brasileiro de Acreditação Hospitalar. 3. ed. Brasília: Ministério da Saúde, 2001. Disponível em : http://www.saude.sp.gov.br/resources/gestor/aceso_rapido/auditoria/manual_acreditacao_hospitalar.pdf. Acesso em 23/07/2008.
- Cunha ICKO, Feldman LB. Avaliação dos serviços de enfermagem: identificação dos critérios de processo dos programas de acreditação hospitalar. Rev Bras Enferm; 2005 jan-fev; 58(1):65-9.
- Feldman LB, Cunha ICKO. Identificação dos critérios de avaliação de resultados do serviço de enfermagem nos programas de acreditação hospitalar. Rev Lat Am Enfermagem; 2006 jul.-ago; 14(4):540-5.
- LeGros N, Pinkall JD. The new JCAHO patient safety standards and the disclosure of unanticipated outcomes. Joint Commission on Accreditation of Healthcare Organizations. J Health Law; 2002; 35(2):189-210.
- McLean RA; Blackwell JL; Stoskopf CH. Accreditation across cultures: a case study. J Allied Health. 2006; 35(2):121-3.
- ONA-Organização Nacional de Acreditação. Avaliação de Organizações Prestadoras de Serviços de Saúde; Normas Técnicas, Normas para o Processo de Avaliação, NA1; Manual da Organização Nacional de Acreditação. Brasília: ONA; 2001. Disponível em: <http://www.ona.org.br>.
- ONA-Organização Nacional de Acreditação. Avaliação de Organizações Prestadoras de Serviços Hospitalares; Normas Técnicas, Normas para o Processo de Avaliação, NA2; Manual da Organização Nacional de Acreditação. Brasília: ONA; 2001. Disponível em: <http://www.ona.org.br>.
- ONA-Organização Nacional de Acreditação. Código de Ética; Normas Técnicas, Norma Orientadora, NO7; Manual da Organização Nacional de Acreditação. Brasília: ONA; 2001. Disponível em: <http://www.ona.org.br>.
- ONA-Organização Nacional de Acreditação. Diretrizes do Sistema e do Processo de Acreditação; Normas Técnicas, Norma Orientadora, NO1; Manual da Organização Nacional de Acreditação. Brasília: ONA; 2001. Disponível em: <http://www.ona.org.br>.
- ONA-Organização Nacional de Acreditação. Manual das Organizações Prestadoras de Serviços Hospitalares, MH1-MH7, Versão 2001; Manual Brasileiro de Acreditação. Manual da Organização Nacional de Acreditação. Brasília: ONA; 2001. Disponível em: <http://www.ona.org.br>.

3. O Paciente diante do diagnóstico do câncer

- Butow PN, Kazemi JN, Beeney LJ, Griffin AM, Dunn SM, Tattersall MH. When the diagnosis is cancer: patient communication experiences and preferences. Cancer. 1996 Jun 15; 77(12):2630-7.
- Costantini M, Morasso G, Montella M, Borgia P, Cecioni R, Beccaro M, Sguazzotti E, Bruzzi P; ISDOC Study Group. Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey. Ann Oncol. 2006 May; 17(5):853-9.
- Davey HM, Butow PN, Armstrong BK. Cancer patients' preferences for written prognostic information provided outside the clinical context. Br J Cancer. 2003 Oct 20; 89(8):1450-6.

- Edwards B, Clarke V. The psychological impact of a cancer diagnosis on families: the influence of family functioning and patients' illness characteristics on depression and anxiety. *Psychooncology*. 2004 Aug;13(8):562-76.
- Ellis PM, Tattersall MH. How should doctors communicate the diagnosis of cancer to patients? *Ann Med*. 1999 Oct;31(5):336-41. Review.
- Fujimori M, Akechi T, Akizuki N, Okamura M, Oba A, Sakano Y, Uchitomi Y. Good communication with patients receiving bad news about cancer in Japan. *Psychooncology*. 2005 Dec;14(12):1043-51
- Gabrijel S, Grize L, Helfenstein E, Brutsche M, Grossman P, Tamm M, Kiss A. Receiving the diagnosis of lung cancer: patient recall of information and satisfaction with physician communication. *J Clin Oncol*. 2008 Jan 10;26(2):297-302.
- Gattellari M, Voigt KJ, Butow PN, Tattersall MH. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? *J Clin Oncol*. 2002 Jan 15;20(2):503-13.
- Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. *J Clin Oncol*. 2004 May 1;22(9):1721-30.
- Lehto US, Ojanen M, Kellokumpu-Lehtinen P. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. *Ann Oncol*. 2005 May;16(5):805-16.
- Lheureux M, Raherison C, Vernejoux JM, Nguyen L, Nocent C, Tunon De Lara M, Taytard A. Quality of life in lung cancer: does disclosure of the diagnosis have an impact? *Lung Cancer*. 2004 Feb;43(2):175-82.
- Miyata H, Tachimori H, Takahashi M, Saito T, Kai I. Disclosure of cancer diagnosis and prognosis: a survey of the general public's attitudes toward doctors and family holding discretionary powers. *BMC Med Ethics*. 2004 Dec 1;5:E7.
- Montazeri A, Hole DJ, Milroy R, McEwen J, Gillis CR. Does knowledge of cancer diagnosis affect quality of life? A methodological challenge. *BMC Cancer*. 2004 May 19;4:21.
- Montazeri A, Tavoli A, Mohagheghi MA, Roshan R, Tavoli Z. Disclosure of cancer diagnosis and quality of life in cancer patients: should it be the same everywhere? *BMC Cancer*. 2009 Jan 29;9:39.
- Noone I, Crowe M, Pillay I, O'Keeffe ST. Telling the truth about cancer: views of elderly patients and their relatives. *Ir Med J*. 2000 Jun;93(4):104-5.
- Nord C, Mykletun A, Fosså SD. Cancer patients' awareness about their diagnosis: a population-based study. *J Public Health Med*. 2003 Dec;25(4):313-7.
- Ong LM, Visser MR, Lammes FB, van Der Velden J, Kuenen BC, de Haes JC. Effect of providing cancer patients with the audiotaped initial consultation on satisfaction, recall, and quality of life: a randomized, double-blind study. *J Clin Oncol*. 2000 Aug;18(16):3052-60.
- Ptacek JT, Ptacek JJ. Patients' perceptions of receiving bad news about cancer. *J Clin Oncol*. 2001 Nov 1;19(21):4160-4.
- Repetto L, Piselli P, Raffaele M, Locatelli C; GIOGer. Communicating cancer diagnosis and prognosis: when the target is the elderly patient—a GIOGer study. *Eur J Cancer*. 2009 Feb;45(3):374-83.
- Rubio Arribas V, Sampedro Martínez E, Zapirain Sarasola M, Gil Benito I, Ayeche Redin S, Tapiz Ibáñez V. [Cancer diagnosis: do we want to know the truth?] *Aten Primaria*. 2004 Apr 30;33(7):368-73. Spanish.
- Salander P. Bad news from the patient's perspective: an analysis of the written narratives of newly diagnosed cancer patients. *Soc Sci Med*. 2002 Sep;55(5):721-32.

- Schofield PE, Beeney LJ, Thompson JF, Butow PN, Tattersall MH, Dunn SM. Hearing the bad news of a cancer diagnosis: the Australian melanoma patient's perspective. *Ann Oncol*. 2001 Mar;12(3):365-71.
- Schofield PE, Butow PN, Thompson JF, Tattersall MH, Beeney LJ, Dunn SM. Psychological responses of patients receiving a diagnosis of cancer. *Ann Oncol*. 2003 Jan;14(1):48-56.
- Winterbottom A, Harcourt D. Patients' experience of the diagnosis and treatment of skin cancer. *J Adv Nurs*. 2004 Nov;48(3):226-33.

4. Perspectivas Atuais e Futuras no Tratamento Oncológico

Câncer de Mama

- Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, Saavedra-Perez D, Morales-Barrera R, Bargallo-Rocha E et al. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer. *Radiat Oncol*. 2009 Jul 11;4(1):24.
- American Cancer Society. Breast cancer facts & figures 2007-2008. Atlanta: American Cancer Society; 2009. Disponível em: http://www.cancer.org/docroot/stt/stt_0.asp. Acesso em 10/07/2009.
- Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline-and taxane-refractory advanced breast cancer. *Oncologist*. 2008 Apr;13(4):361-9.
- Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. *J Transl Med*. 2008 May 16;6:25.
- Berezovsky A, Salomão SR, Pereira JM, Sacai PY, Chojniak MMM. Eletroretinograma multifocal em pacientes tratadas com tamoxifeno em baixa dosagem. *Arq Bras Oftalmol*. 2004 Aug;67(4):631-35.
- Bermejo Aycart JI, Iniesta Pérez S, Redondo Martín T, Gallego Villaescusa I, García Andrade MC. Sarcomas de útero después de tratamiento con tamoxifeno por cáncer de mama. *Oncología*. 2005 Jul;28(7):38-42.
- Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. *Ann Oncol*. 2007 Jun;18 (Suppl 6):vi26-30.
- Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. *Oncologist*. 2008 May;13(5):515-25.
- Canello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. *Breast Cancer Res*. 2008;10(4):R60.
- Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. *Clin Cancer Res*. 2008 Mar 15;14(6):1744-52.
- Charafe-Jauffret E, Ginestier C, Birnbaum D. Breast cancer stem cells: tools and models to rely on. *BMC Cancer*. 2009 Jun 25;9:202.
- Dahabreh IJ, Linardou H, Siannis F, Fountzilias G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Oncologist*. 2008 Jun;13(6):620-30.
- DeLaurentiis M, Canello G, Diego D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *J Clin Oncol* 2008; 26(1): 44-53.

- Dendukuri N, Khetani K, Mclsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. *CMAJ*. 2007 May 8;176(10):1429-34.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; 365(9472): 1687-1717.
- Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. *Cancer*. 2007 Aug 1;110(3):489-98.
- Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. *Oncologist*. 2007 Jul;12(7):766-73.
- Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. *J Clin Oncol* 2009; 27(Supplement): 15s. Abstract 502.
- Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. *Mol Cancer Ther*. 2007 May;6(5):1629-40.
- Heywang-Köbrunner SH, Schreer I, Heindel W, Katalinic A. Imaging studies for the early detection of breast cancer. *Dtsch Arztebl Int*. 2008 Aug;105(31-32):541-7.
- Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. *Am J Clin Pathol*. 2008 Feb;129(2):263-73.
- Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. *Clin Cancer Res*. 2008 May 15;14(10):3070-6.
- Hudis CA. Drug therapy: trastuzumab-mechanism of action and use in clinical practice. *N Eng J Med* 2007; 357(1):39-51.
- Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? *Breast Cancer*. 2007;14(2):156-62.
- Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. *Br J Cancer*. 2009 Mar 10;100(5):684-92.
- Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ*. 2009 Jul 9;339:b2587.
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents : defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006; 24(14): 2137-50.
- Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. *Cancer*. 2008 Apr 1;112(7):1437-44.
- Lette J, Lette F. Screening for breast cancer should be an integral part of myocardial perfusion imaging. *Can J Cardiol*. 2009 Jul;25(7):e267.
- Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. *BMC Genomics*. 2008 May 22;9:239.

- Martins SJ, Yamamoto CA. Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer. *Rev Assoc Med Bras*. 2008 Nov-Dec; 54(6):494-9.
- Montemurro F, Redana S, Nolè F, Donadio M, Jacomuzzi ME, Valabrega G et al. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. *BMC Cancer*. 2008 Jul 24; 8:209.
- Mosley JD, Keri RA. Intrinsic bias in breast cancer gene expression data sets. *BMC Cancer*. 2009 Jun 29; 9(1):214.
- Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. *Oncologist*. 2006 Nov-Dec; 11(10):1047-57. Review.
- Muñoz A, Carrera S, Ferreiro J, de Lobera AR, Mañé JM, López-Vivanco G. Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. *Ann Oncol*. 2007 Dec; 18(12):2045-6.
- Munshi A. Resource-sparing and cost-effective strategies in current management of breast cancer. *J Cancer Res Ther*. 2009 Apr-Jun; 5(2):116-20.
- Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. *Mol Cancer Ther*. 2007 Feb; 6(2):667-74.
- National Cancer Institute (NCI). Breast Cancer Screening : PDQ. Last Modified: 06/24/2009. Disponível em: <http://www.cancer.gov/cancertopics/pdq/screening/breast/>. Acesso em 10/07/2009.
- National Cancer Institute (NCI). Surveillance, epidemiology and end results (1983-1987). Disponível em: <http://seer.cancer.gov/>. Acesso em 10/07/2009.
- Pastore AR. O valor da ultra-sonografia na avaliação das alterações endometriais em pacientes portadoras de câncer de mama e tratadas com tamoxifeno. *Radiol Bras*. 2007 Dec; 40(6):6-8.
- Pereira de Godoy JM, Da Silva SH, De Fatima Guerreiro Godoy M. Mechanisms used to face difficulties encountered following surgical treatment for breast cancer. *Afr J Psychiatry (Johannesbg)*. 2009 Feb; 12(1):75-6.
- Perez EA, Romond EH, Suman VJ et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. *J Clin Oncol* 2007; 25(Supplement):18s. Abstract 512.
- Petrelli F, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. *Oncologist*. 2008 Apr; 13(4):373-81.
- Pietrowska M, Marczak L, Polanska J, Behrendt K, Nowicka E, Walaszczyk A et al. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. *J Transl Med*. 2009 Jul 13; 7(1):60.
- Rizwan MM, Saadullah M. Lack of awareness about breast cancer and its screening in developing countries. *Indian J Cancer*. 2009 Jul-Sep; 46(3):252-3.
- Robert NJ, Eiermann W, Pienkowski T et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up. *J Clin Oncol* 2007; 25(Supplement):18s. Abstract 19647.
- Ross JS, Slodkowska EA, Symmans WF, Puztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. *Oncologist*. 2009 Apr; 14(4):320-68.

- Sarvazyan A, Egorov V, Son JS, Kaufman CS. Cost-Effective Screening for Breast Cancer Worldwide: Current State and Future Directions. *Breast Cancer*. 2008 Jul 2;1:91-99.
- Schmidt C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research. *J Natl Cancer Inst*. 2008 May 21;100(10):694-5.
- Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Trastuzumab treatment for breast cancer during pregnancy. *Can Fam Physician*. 2008 Jan;54(1):31-2.
- Sinclair S, Zimmer AS, Swain SM. HER-2 Targeting agents and antiangiogenic therapy: evolution of adjuvant therapy in breast cancer. *Asco Educational Book* 2009; 3-10.
- Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet* 2007; 369(9555):29-36.
- Stavrou D, Weissman O, Polyniki A, Papageorgiou N, Haik J, Farber N et al. Quality of life after breast cancer surgery with or without reconstruction. *Eplasty*. 2009 Jun 2;9:e18.
- Tuma RS. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. *J Natl Cancer Inst*. 2007 Mar 7;99(5):348-9.
- Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. *J Clin Oncol* 2009; 27(Supplement):18s. Abstract CRA501.
- Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA et al. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. *Breast Cancer Res*. 2008;10(5):R88.
- Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. *BMC Cancer*. 2007 Aug 8;7:153.
- Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of ER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2002; 20(3):719-26.
- Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens. *BMC Cancer*. 2009 Jul 11;9(1):226.
- Wolff AC, Cianfrocca ME, Johnston SRD. Optimizing endocrine therapy for women with breast cancer regardless of menopausal status. *Asco Educational Book* 2006; 22-9.
- Yin CS. Tamoxifen: to use or not to use. *Taiwan J Obstet Gynecol*. 2008 Mar;47(1):129-30.
- Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. *Mol Cancer Ther*. 2008 Jul;7(7):1846-50.

Câncer de Pulmão

- Ademuyiwa FO, Hanna N. Cetuximab in non-small cell lung cancer. *Expert Opin Biol Ther*. 2008 Jan; 8(1):107-13.
- Alam N, Darling G, Evans WK, Mackay JA, Shepherd FA; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. *Crit Rev Oncol Hematol*. 2006 May; 58(2):146-55.
- Asamura H. Treatment of choice for stage I non-small cell lung cancer: surgery or radiotherapy? *J Thorac Oncol*. 2006 Oct; 1(8):766-7.

- Azzoli CG. Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer? *Nat Clin Pract Oncol*. 2005 Nov; 2(11):552-3.
- Baltayiannis N, Bolanos N, Anagnostopoulos D, Sfyridis P, Georgiannakis E, Zografos P, et al. Surgery in small cell lung cancer: when and why. *J BUON*. 2005 Oct-Dec; 10(4):459-472.
- Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. *Cancer*. 2008 Nov 1; 113(9):2512-7.
- Belani CP. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. *Semin Oncol*. 2005 Apr; 32(2 Suppl 2):S9-15.
- Belani CP. Early-stage non-small-cell lung cancer: adjuvant versus neoadjuvant chemotherapy. *Clin Lung Cancer*. 2003 Jul; 5(1):11-2.
- Besse B, Le Chevalier T. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? *J Clin Oncol*. 2008 Nov 1; 26(31):5014-7.
- Betticher DC. Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. *Lung Cancer*. 2005 Dec; 50S2:S9-S16.
- Bischof M, Debus J, Herfarth K, Muley T, Kappes J, Storz K, et al. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. *Strahlenther Onkol*. 2007 Dec; 183(12):679-84.
- Bogart JA, Govindan R. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. *Clin Lung Cancer*. 2006 Jan; 7(4):285-7.
- Booth CM, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. *J Thorac Oncol*. 2006 Feb; 1(2):180-7.
- Bouchard N, Laberge F, Raby B, Martin S, Lacasse Y. Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. *Can Respir J*. 2008 Jul-Aug; 15(5):270-4.
- Brahmer JR, Ettinger DS. Non-small cell lung cancer: adjuvant and neoadjuvant chemotherapy. *Respirology*. 2007 May; 12(3):320-5.
- Bria E, Cuppone F, Cecere FL, Milella M, Nisticò C, Cognetti F, et al. Adjuvant chemotherapy for non-small cell lung cancer. *J Thorac Oncol*. 2007 May; 2(5 Suppl):S7-11.
- Cangiano R. Adjuvant chemotherapy in resected non-small cell lung cancer. *Rays*. 2004 Oct-Dec; 29(4):435-7.
- Chang MY, Sugarbaker DJ. Surgery for early stage non-small cell lung cancer. *Semin Surg Oncol*. 2003; 21(2):74-84.
- Cheong KA, Chrystal K, Harper PG. Adjuvant chemotherapy in non-small cell lung cancer. *Int J Clin Pract*. 2007 Jan; 61(1):143-6.
- Crane EJ, Simon G. Adjuvant chemotherapy for non-small cell lung cancer. *Curr Treat Options Oncol*. 2006 Jan; 7(1):51-8.
- Custodio Carretero AB, García Sáenz JA, González Larriba JL, Bobokova J, Calles Blanco A, et al. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. *Clin Transl Oncol*. 2008 Sep; 10(9):560-71.
- D'Amato TA. Adjuvant chemotherapy and the role of chemotherapy resistance testing for stage I non-small cell lung cancer. *Thorac Surg Clin*. 2007 May; 17(2):287-99.
- D'Amico TA. Adjuvant chemotherapy for non-small cell lung cancer. *Semin Thorac Cardiovasc Surg*. 2005 Fall; 17(3):195-8.
- Deslauriers J, Grégoire J. Surgical therapy of early non-small cell lung cancer. *Chest*. 2000 Apr; 117(4 Suppl 1):104S-109S.
- Dominioni L, Imperatori A, Rovera F, Ochetti A, Torrigiotti G, Paolucci M. Stage I nonsmall cell lung carcinoma: analysis of survival and implications for screening. *Cancer*. 2000 Dec 1; 89(11 Suppl):2334-44.

- Dômont J, Soria JC, Le Chevalier T. Adjuvant chemotherapy in early-stage non-small cell lung cancer. *Semin Oncol*. 2005 Jun; 32(3):279-83.
- Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. *Mol Cancer Ther*. 2007 Oct; 6(10):2642-51.
- Dubey S, Schiller JH. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. *Oncologist*. 2005 Apr; 10(4):282-91.
- Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. *Clin Cancer Res*. 2005 Jul 1; 11(13 Pt 2):5017s-5021s.
- Edelman MJ, Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. *Curr Treat Options Oncol*. 2002 Feb; 3(1):67-73.
- Endo C, Sagawa M, Sakurada A, Sato M, Kondo T, Fujimura S. Surgical treatment of stage I non-small cell lung carcinoma. *Ann Thorac Cardiovasc Surg*. 2003 Oct; 9(5):283-9.
- Felip E, Cedrés S, Peralta S, Prat A. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). *Ann Oncol*. 2007 Jul; 18 Suppl 9:ix143-6.
- Govindan R. Cetuximab in advanced non-small cell lung cancer. *Clin Cancer Res*. 2004 Jun 15; 10(12 Pt 2):4241s-4244s
- Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. *J Clin Oncol*. 2006 Nov 20; 24(33):5253-8.
- Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. *Drugs Today (Barc)*. 2005 Feb; 41(2):107-27.
- Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. *J Clin Oncol*. 2004 Oct 1; 22(19):3860-7.
- Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. *Expert Opin Pharmacother*. 2004 Jul; 5(7):1621-33
- Inoue M, Miyoshi S, Yasumitsu T, Mori T, Iuchi K, Maeda H, Matsuda H. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. *Ann Thorac Surg*. 2000 Nov; 70(5):1615-9.
- Jassem J. Postoperative chemotherapy in non-small cell lung cancer: still more questions than answers. *Future Oncol*. 2006 Oct; 2(5):569-71.
- Jazieh AR, Kyasa MJ, Sethuraman G, Howington J. Disparities in surgical resection of early-stage non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2002 Jun; 123(6):1173-6.
- Kim ES, Mauer AM, William WN Jr, Tran HT, Liu D, Lee JJ, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer. *Cancer*. 2009 Feb 10.
- Kim ES. Cetuximab as a single agent or in combination with chemotherapy in lung cancer. *Clin Lung Cancer*. 2004 Dec; 6 Suppl 2:S80-4.
- Lara PN Jr, Ramalingam SS. Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. *Clin Lung Cancer*. 2008 May; 9(3):141-3.
- Lilenbaum RC. The evolving role of cetuximab in non-small cell lung cancer. *Clin Cancer Res*. 2006 Jul 15; n12(14 Pt 2):4432s-4435s.
- Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. *Cochrane Database Syst Rev*. 2005 Jan 25; (1):CD004699.

- Morgensztern D, Govindan R. Is there a role for cetuximab in non small cell lung cancer? *Clin Cancer Res*. 2007 Aug 1; 13(15 Pt 2):s4602-5
- Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. *Am J Respir Crit Care Med*. 2008 Mar 1; 177(5):516-23.
- Park JH, Lee CT, Lee HW, Baek HJ, Zo JI, Shim YM. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. *Eur J Cardiothorac Surg*. 2005 Jun; 27(6):1086-91.
- Passlick B. Initial surgical staging of lung cancer. *Lung Cancer*. 2003 Dec; 42 Suppl 1:S21-5.
- Pearson FG. Non-small cell lung cancer: role of surgery for stages I-III. *Chest*. 1999 Dec; 116(6 Suppl):500S-503S.
- Pirker R. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer. *Clin Adv Hematol Oncol*. 2008 Oct; 6(10):735-6.
- Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. *N Engl J Med*. 2005 Jun 23; 352(25):2640-2.
- Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer. *Clin Adv Hematol Oncol*. 2003 Sep; 1(9):533-7
- Potti A, Ganti AK. Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future. *Expert Opin Biol Ther*. 2006 Jul; 6(7):709-16
- Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. *Clin Cancer Res*. 2005 Jan 15; 11(2 Pt 1):795-805.
- Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. *Ann Oncol*. 2008 Feb; 19(2):362-9.
- Rossi A, Bria E, Maione P, Palazzolo G, Falanga M, Gridelli C. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer. *Rev Recent Clin Trials*. 2008 Sep; 3(3):217-27.
- Rossi A, Maione P, Gridelli C. Cetuximab in advanced non-small cell lung cancer. *Crit Rev Oncol Hematol*. 2006 Aug; 59(2):139-49.
- Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. *Cancer Sci*. 2007 Sep; 98(9):1498-503.
- Sartore-Bianchi A, Cerea G, Schiavetto I, Giannetta L, Ricotta R, Maugeri MR, et al. Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. *Ann Oncol*. 2006 Mar; 17 Suppl 2:ii49-51.
- Scagliotti G, Novello S. Adjuvant chemotherapy after complete resection for early stage NSCLC. *Lung Cancer*. 2003 Dec; 42 Suppl 1:S47-51.
- Scagliotti GV, Novello S. Current development of adjuvant treatment of non-small-cell lung cancer. *Clin Lung Cancer*. 2004 Dec; 6 Suppl 2:S63-70.
- Scagliotti GV, Novello S. Current status of adjuvant chemotherapy in NSCLC. *Ann Oncol*. 2006 May; 17 Suppl 5:v62-3.
- Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kannies F, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. *Cancer Immunol Immunother*. 2007 Oct; 56(10):1637-44.
- Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, et al. Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. *Acta Oncol*. 2007; 46(4):547-9.

- Socinski MA. Adjuvant therapy of resected non-small-cell lung cancer. *Clin Lung Cancer*. 2004 Nov; 6(3):162-9.
- Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. *Clin Cancer Res*. 2007 Aug 1; 13(15 Pt 2):s4597-601
- Solomon B, Mitchell JD, Bunn PA Jr. Adjuvant chemotherapy for resected non-small-cell lung cancer. *Oncology (Williston Park)*. 2005 Nov;19(13):1685-97; discussion 1698-700, 1705.
- Tiseo M, Franciosi V, Grossi F, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? *Eur J Cancer*. 2006 Jan;42(1):8-16.
- Treece SJ, Magee L, Gilligan D, Harden SV. Adjuvant chemotherapy in non-small cell lung cancer -- how feasible is it in a non-trial population? *Clin Oncol (R Coll Radiol)*. 2007 Oct; 19(8):629-30.
- Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. *Ann Thorac Cardiovasc Surg*. 2007 Apr; 13(2):73-7.
- Vansteenkiste JF, Schildermans RH. The future of adjuvant chemotherapy for resected non-small cell lung cancer. *Expert Rev Anticancer Ther*. 2005 Feb; 5(1):165-75.
- Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. *Chest*. 2005 Oct;128(4):2933-43.
- Wakelee H, Chhatwani L. Adjuvant chemotherapy for resected non-small cell lung cancer. *Semin Thorac Cardiovasc Surg*. 2008 Fall; 20(3):198-203
- Wilhelm L, Kolesar JM. Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer. *Am J Health Syst Pharm*. 2005 Jul 1; 62(13):1365-9.
- Wozniak AJ, Gadgeel SM. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further? *Oncology (Williston Park)*. 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82.
- Zorn GL 3rd, Nesbitt JC. Surgical management of early stage lung cancer. *Semin Surg Oncol*. 2000 Mar;18(2):124-36.

5. Análise do Custo com as Complicações do Catéter Totalmente Implantável

- Basile-Filho A, Castro PTO, Pereira Júnior GA, Marson F, Mattar Júnior L, Costa JC. Sepsis primária, relacionada ao cateter venoso central. *Medicina (Ribeirão Preto)*. 1998; 31(3):363-8.
- Biffi R, Corrado F, de Braud F, de Lucia F, Scarpa D, Testori A, et al. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. *Eur J Cancer*. 1997 Jul;33(8):1190-4.
- Biffi R, De Braud F, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. *Cancer*. 2001 Sep 1;92(5):1204-12.
- Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. *Ann Oncol*. 1998 Jul;9(7):767-73.
- Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. *Ann Oncol*. 2009 May;20(5):935-40.

- Bow EJ, Kilpatrick MG, Clinch JJ. Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: a randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life. *J Clin Oncol*, 17(4):1267. april ,1999. Disponível em <http://jco.ascopubs.org/cgi/content/full/17/4/1267>. Acessado: 21/03/2008.
- Brandão MÃ, Rodrigues Z, Sampaio S, Acioli J, Sampaio C. Cateter venoso totalmente implantável em 278 pacientes oncológicos. *Rev. bras. Cancerol.* 2000;46(1):49-56.
- Brenner Friedmann P, Buggedo Tarraza G, Calleja Rodríguez MD, Del Valle M G, Fica C A, Gómez Olivares ME, et al. Prevención de infecciones asociadas a catéteres vasculares centrales. *Rev chi infectol.* 2003;20(1):51-69.
- Brothers TE, Von Moll LK, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD. Experience with subcutaneous infusion ports in three hundred patients. *Surg Gynecol Obstet.* 1988 Apr;166(4):295-301.
- Broviac JW, Cole JJ, Scribner BH. A silicone rubber atrial catheter for prolonged parenteral alimentation. *Surg Gynecol Obstet.* 1973 Apr;136(4):602-6.
- Brown DF, Muirhead MJ, Travis PM, Vire SR, Weller J, Hauer-Jensen M. Mode of chemotherapy does not affect complications with an implantable venous access device. *Cancer.* 1997 Sep 1;80(5):966-72.
- Brungs S, Render ML. Using evidence –based practice to reduce central line infections. *Clin J Oncol Nurs.* 2006; 10(6):723-5. Disponível ; <http://www.ons.org/publications/journals/CJON/Volume10/Issue6/pdf/1006723.pdf>
- Camp-Sorrell D. Implanted ports: skin erosion. *Clin J Oncol Nurs.* 2004 Jun;8(3):309-10.
- Carvalho RM, Joviliano EE, Kawano MY, Gomes CAP, Souza AC, Cherri J, et al. Acesso venoso central de longa duração. Experiência com 79 cateteres em 66 pacientes. *Medicina (Ribeirão Preto);* 1999; 32(1):97-101.
- CENTER FOR DISEASE CONTROL AND PREVENTION, CDC-P. Guidelines for the prevention of intravascular catheter-related infections, *MMWR*, 2002; 51(10):1-29.
- Chang CL, Chen HH, Lin SE .Catheter fracture and cardiac migration--an unusual fracture site of totally implantable venous devices: report of two cases. *Chang Gung Med J.* 2005 Jun;28(6):425-30.
- Charvát J, Linke Z, Horáèková M, Prausová J. Implantation of central venous ports with catheter insertion via the right internal jugular vein in oncology patients: single center experience. *Support Care Cancer.* 2006 Nov;14(11):1162-5.
- Coopersmith CM, Rebmann TL, Zack JE, Ward MR, Corcoran RM, Schallom ME, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. *Crit Care Med.* 2002 Jan;30(1):59-64.
- Di Carlo I, Cordio S, La Greca G. Totally implantable venous access devices implanted surgically: a retrospective study on early and late complications. *Arch Surg.* 2001;136(9):1050-3.
- Figueiredo LFP, Capone Neto A. Como identificar, tratar e prevenir a embolia gasosa relacionada a cateteres venosos centrais? *Rev Assoc Med Bras.* 2001;47(3):179-80.
- Godoy JL, Otta EK, Miyazaki RA, Bitencourt MA, Pasquini R. Central venous access through the external jugular vein in children submitted to bone marrow transplantation. *Braz arch biol technol;* 2005;48(1):41-4.
- Gonçalves AR, Carvalho RV, Coelho SO, Gutierrez FNG, Bach RVW, Finoquio R, Santana G. Escolha do braço como sítio de implantação do cateter venoso central de longa permanência em crianças: experiência do Serviço de Cirurgia Pediátrica do Hospital do Câncer Hospital do Câncer I -INCA - Rio de

- Janeiro. *Revista Brasileira de Cancerologia*. 2005;12(4):305-11. Disponível em:
<http://www.fc.up.pt/fcup/news/?hist=&lang=pt&view=f3&page=0&op=view&id=849>. Acessado em 18/08/2008.
- Groeger JS, Lucas AB, Thaler HT, Friedlander-Klar H, Brown AE, Kiehn TE, Armstrong D. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. *Ann Intern Med*. 1993 Dec 15;119(12):1168-74.
 - Guaresti G, Della Latta MP, Rivas N. Terapia de bloqueio: una nueva modalidad para el tratamiento de infecciones relacionadas con catéteres implantables. *Arch. argent. pediatr*; 2004;102(3):211-3. Disponível em: http://www.sap.org.ar/staticfiles/archivos/2004/arch04_3/%20A3.211-213.pdf. Acesso em 01 de julho de 2008.
 - Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt H, Ho AD. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. *Cancer*. 2002 Jan 1;94(1):245-51.
 - Higuera F, Rosenthal VD, Duarte P, Ruiz J, Franco G, Safdar N. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in México. *Crit Care Med*, 2005; 33(9):2022-7.
 - Kalil AN, Mastalir ET, Riccardi F, MádkeGR, Pilla ES. Cateteres venosos totalmente implantáveis em pacientes com neoplasia hematológica e não hematológica. *Rev Col Bras Cir*, 2001;28(6):401-3.
 - Knutstad K, Hager B, Hauser M. Radiologic diagnosis and management of complications related to central venous access. *Acta Radiol*. 2003 Sep;44(5):508-16. Review.
 - Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. *World J Surg*. 1998 Jan;22(1):12-6.
 - Kurul S, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. *Lancet Oncol*. 2002 Nov;3(11):684-92. Review.
 - Lopes RAM, Gomede SLA, Silva ARB, Rosa TCM. Atuação da enfermagem na utilização do catéter venoso totalmente implantável (CVTI). *Rev Bras Enferm*. 1993; 46(2):132-5.
 - Mangini C. Infecção Relacionada a Cateteres Vasculares de Longa Permanência. *Rev Prática Hospitalar*. 39:mai-jun, 2005. Disponível em: <http://www.praticahospitalar.com.br/pratica%2039/pgs/materia%2009-39.html>. Acesso em: 07/07/2008.
 - Marcondes CRR, Biojone CR, Cherri J, Moryia T, Piccinato CE. Complicações precoces e tardias em acesso venoso central. Análise de 66 implantes. *Acta Cir Bras*. 2000;15(supl 2):73-75. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502000000600023&lng=en. doi: 10.1590/S0102-86502000000600023.
 - Martins LMM, Lima AR. Cuidados com o paciente que utiliza o cateter de Hickman-Broviac: um estudo de caso. *Rev Esc Enferm. USP*; 1998; 32(3):187-91.
 - Mermel LA. Prevention of intravascular catheter-related infections. *Ann Intern Med*. 2000 Mar 7;132(5):391-402. Erratum in: *Ann Intern Med* 2000 Sep 5;133(5):395.
 - Miranda RB, Lopes JRA, Cavalcante RN, Kafajian O. Perviedade e complicações no seguimento de cateteres venosos totalmente implantáveis para quimioterapia. *J vasc bras*. 2008;7(4):316-20.
 - Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. *Surgery*. 1982 Oct;92(4):706-12.

- Nishinari K, Malavolta LC, Saes GF, Langer M, Carvalho Sobrinho A, Zerati AE, Yazbek G, Wolosker N. Cateteres venosos totalmente implantáveis para quimioterapia: experiência em 415 pacientes. *Acta oncol bras*; 2003 abr.jun.; 23(2).
- O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep*. 2002 Aug 9; 51(RR-10): 1-29.
- Paoletti F, Ripani U, Antonelli M, Nicoletta G. Central venous catheters. Observations on the implantation technique and its complications. *Minerva Anestesiol*. 2005 Sep; 71(9):555-60. Review
- Pracchia LF, Dias LCS, Dorlhiac-Llacer PE, Chamone DAF. Comparison of catheter-related infection risk in two different long-term venous devices in adult hematology-oncology patients. *Rev. Hosp. Clin. Fac. Med. Univ. São Paulo*; 2005; 59(5):291-5.
- Reed WP, Newman KA, de Jongh C, Wade JC, Schimpff SC, Wiernik PH, et al. Prolonged venous access for chemotherapy by means of the Hickman catheter. *Cancer*, 1983; 52 (1):185-92.
- Render ML, Brungs S, Kotagal U, Nicholson M, Burns P, Ellis D, Clifton M, Fardo R, Scott M, Hirschhorn L. Evidence-based practice to reduce central line infections. *Jt Comm J Qual Patient Saf*. 2006 May; 32(5):253-60.
- Schlangen JT, Debets JM, Wils JA. The 'pinch-off phenomenon': a radiological symptom for potential fracture of an implanted permanent subclavian catheter system. *Eur J Radiol*. 1995 Jul; 20(2):112-3.
- Schwarz RE, Groeger JS, Coit DG. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. *Cancer*. 1997 Apr 15; 79(8):1635-40.
- Stonelake PA, Bodenham AR. The carina as a radiological landmark for central venous catheter tip position. *Br J Anaesth*. 2006 Mar; 96(3):335-40.
- Stuart RK, Shikora SA, Akerman P, Lowell JA, Baxter JK, Apovian C, et al. Incidence of arrhythmia with central venous catheter insertion and exchange. *JPEN J Parenter Enteral Nutr*. 1990 Mar-Apr; 14(2):152-5.
- Teixeira JC, Santos CC, Pereira SR, Santos ACP. Avaliação da instalação e da utilização de sistemas para acesso venoso central totalmente implantável em mulheres com câncer. *Rev. bras. mastologia*; 2001; 11(4):132-6.
- Vesely TM. Central venous catheter tip position: a continuing controversy. *J Vasc Interv Radiol*. 2003 May; 14(5):527-34.
- Vialei PH. Complications associated with implantable vascular access devices in the patient with cancer. *J Inf Nurs*. 2003; 26(2):97-102.
- Wolosker N, Yazbek G, Munia MA, Zerati AE, Langer M, Nishinari K. Totally implantable femoral vein catheters in cancer patients. *Eur J Surg Oncol*. 2004 Sep; 30(7):771-5.
- Wolosker N, Yazbek G, Nishinari K, Malavolta LC, Munia MA, Langer M, Zerati AE. Totally implantable venous catheters for chemotherapy: experience in 500 patients. *Sao Paulo Med J*. 2004 Jul 1; 122(4):147-51.

6. O Bem estar e a qualidade de vida da criança com Câncer

- Af Sandeberg M, Johansson E, Björk O, Wettergren L. Health-related quality of life relates to school attendance in children on treatment for cancer. *J Pediatr Oncol Nurs*. 2008; 25(5): 265-74.
- Alessi D, Dama E, Barr R, Mosso ML, Maule M, Magnani C, Pastore G, Merletti F. Health-related quality of life of long-term childhood cancer survivors: a population-based study from the Childhood Cancer Registry of Piedmont, Italy. *Eur J Cancer*. 2007; 43(17): 2545-52.

- Alessi D, Pastore G, Zuccolo L, Mosso ML, Richiardi L, Pearce N, Magnani C, Merletti F. Analysis of nonresponse in the assessment of health-related quality of life of childhood cancer survivors. *Eur J Cancer Prev.* 2007 Dec; 16(6): 576-80.
- Banks BA, Barrowman NJ, Klaassen R. Health-related quality of life: changes in children undergoing chemotherapy. *J Pediatr Hematol Oncol.* 2008; 30(4): 292-7.
- Beck ARM, Lopes MHB. Cuidadores de crianças com câncer: aspectos da vida afetados pela atividade de cuidador. *Rev Bras Enferm.* 2007; 60(6): 670-5.
- Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, et al. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. *J Clin Oncol.* 2005; 23(24): 5493-500.
- Bitsko MJ, Stern M, Dillon R, Russell EC, Laver J. Happiness and time perspective as potential mediators of quality of life and depression in adolescent cancer. *Pediatr Blood Cancer.* 2008; 50(3): 613-9.
- Blaauwbroek R, Groenier KH, Kamps WA, Meyboom-de Jong B, Postma A. Late effects in adult survivors of childhood cancer: the need for life-long follow-up. *Ann Oncol.* 2007; 18(11): 1898-902.
- Calaminus G, Weinspach S, Teske C, Gobel U. Quality of survival in children and adolescents after treatment for childhood cancer: the influence of reported late effects on health related quality of life. *Klin Padiatr.* 2007; 219(3): 152-7.
- Calaminus G; Barr R. Economic evaluation and health-related quality of life. *Pediatr Blood Cancer.* 2008; 50(5 Suppl): 1112-5.
- De Bolle M, De Clercq B, De Fruyt F, Benoit Y. Self-and parental perspectives on quality of life in children with cancer. *J Psychosoc Oncol.* 2008; 26(2): 35-47.
- De Vries MA, Van Litsenburg RR, Huisman J, Grootenhuis MA, Versluys AB, Kaspers GJ, Gemke RJ. Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. *Health Qual Life Outcomes;* 6:103, 2008.
- Dolgin MJ, Somer E, Buchvald E, Zaizov R. Quality of life in adult survivors of childhood cancer. *Soc Work Health Care.* 1999; 28(4): 31-43.
- Dow KH, Ferrell BR, Haberman MR, Eaton L. The meaning of quality of life in cancer survivorship. *Oncol Nurs Forum.* 1999 Apr; 26(3): 519-28.
- Eiser C, Eiser JR, Greco V. Surviving childhood cancer: quality of life and parental regulatory focus. *Pers Soc Psychol Bull.* 2004 Feb.; 30(2): 123-33.
- Eiser C, Eiser JR, Stride CB. Quality of life in children newly diagnosed with cancer and their mothers. *Health Qual Life Outcomes;* 3: 29, 2005.
- Eiser C. Beyond survival: quality of life and follow-up after childhood cancer. *J Pediatr Psychol.* 2007; 32(9): 1140-50.
- Ferrell BR, Virani R, Smith S, Juarez G; National Cancer Policy Board and Institute of Medicine. The role of oncology nursing to ensure quality care for cancer survivors: a report commissioned by the National Cancer Policy Board and Institute of Medicine. *Oncol Nurs Forum.* 2003 Jan-Feb; 30(1): E1-E11. Review.
- Frances JM, Morris CD, Arkader A, Nikolic ZG, Healey JH. What is quality of life in children with bone sarcoma? *Clin Orthop Relat Res.* 2007; 459: 34-9.
- Gerber NU, Zehnder D, Zuzak TJ, Poretti A, Boltshauser E, Grotzer MA. Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life. *Arch Dis Child.* 2008; 93(7): 582-9.
- Grant J, Cranston A, Horsman J, Furlong W, Barr N, Findlay S, Barr R. Health status and health-related quality of life in adolescent survivors of cancer in childhood. *J Adolesc Health.* 2006 May; 38(5): 504-10.

- Hinds PS, Burghen EA, Haase JE, Phillips CR. Advances in defining, conceptualizing, and measuring quality of life in pediatric patients with cancer. *Oncol Nurs Forum*. 2006. 33(1 Suppl): 23-9.
- Jankovic M, Van Dongen-Melman JE, Vasilatou-Kosmidis H, Jenney ME. Improving the quality of life for children with cancer. *European School of Oncology Advisory Group. Tumori*. 1999 Jul-Aug.; 85(4): 273-9.
- Jurbergs N, Russell KM, Long A, Phipps S. Adaptive style and differences in parent and child report of health-related quality of life in children with cancer. *Psychooncology*. 2008; 17(1): 83-90.
- King CR, Haberman M, Berry DL, Bush N, Butler L, Dow KH, et al. Quality of life and the cancer experience: the state-of-the-knowledge. *Oncol Nurs Forum*. 1997; 24(1): 27-41.
- King CR, Hinds P, Dow KH, Schum L, Lee C. The nurse's relationship-based perceptions of patient quality of life. *Oncol Nurs Forum*. 2002 Nov-Dec; 29(10): E118-26
- King CR. Advances in how clinical nurses can evaluate and improve quality of life for individuals with cancer. *Oncol Nurs Forum*. 2006 Jan; 33(1 Suppl): 5-12. Review.
- Landolt MA, Vollrath M, Niggli FK, Gnehm HE, Sennhauser FH. Health-related quality of life in children with newly diagnosed cancer: a one year follow-up study. *Health Qual Life Outcomes*; 4: 63, 2006.
- Lopes VF, Silva JLL, Andrade M. A percepção de profissionais de enfermagem sobre os cuidados paliativos ao cliente oncológico pediátrico fora de possibilidade de cura: um estudo na abordagem fenomenológica das relações humanas. *Online braz j nurs*. (Online). 2007; 6(3).
- Matziou V, Perdikaris P, Feloni D, Moshovi M, Tsoumakas K, Merkouris A. Cancer in childhood: children's and parents' aspects for quality of life. *Eur J Oncol Nurs*. 2008; 12(3): 209-16.
- Maurice-Stam H, Grootenhuis MA, Brons PP, Caron HN, Last BF. Psychosocial indicators of health-related quality of life in children with cancer 2 months after end of successful treatment. *J Pediatr Hematol Oncol*. 2007; 29(8): 540-50.
- Meeske KA, Patel SK, Palmer SN, Nelson MB, Parow AM. Factors associated with health-related quality of life in pediatric cancer survivors. *Pediatr Blood Cancer*. 2007; 49(3): 298-305.
- Misko MD, Bousso RS. Managing cancer and its interurrences: the family deciding to seek emergency care for the child. *Rev Lat Am Enfermagem*. 2007; 15(1): 48-54.
- Ortiz MCA, Lima RAG. Experiences of families with children and adolescents after completing a cancer treatment: support for the nursing care. *Rev Lat Am Enfermagem*. 2007; 15(3): 411-7.
- Penn A, Lewis SP, Hunt LP, Shortman RI, Stevens MC, McCarter RL, Curran AL, Sharples PM. Health related quality of life in the first year after diagnosis in children with brain tumours compared with matched healthy controls; a prospective longitudinal study. *Eur J Cancer*. 2008; 44(9): 1243-52.
- Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME, Hawkins MM. The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions. *Health Qual Life Outcomes*; 4: 77, 2006.
- Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. *J Clin Oncol*. 2009; 27(14): 2308-18.
- Russell KM, Hudson M, Long A, Phipps S. Assessment of health-related quality of life in children with cancer: consistency and agreement between parent and child reports. *Cancer*. 2006; 106(10): 2267-74.

- Sapolnik R. Suporte de terapia intensiva no paciente oncológico. J Pediatr (Rio J); 2003; 79(supl.2): S231-S242.
- Scarpelli AC, Paiva SM, Pordeus IA, Ramos-Jorge ML, Varni JW, Allison PJ. Measurement properties of the Brazilian version of the Pediatric Quality of Life Inventory (PedsQL) cancer module scale. Health Qual Life Outcomes. 6: 7, 2008.
- Shimoda S, Horsman J, Furlong W, Barr R, de Camargo B. Disability and health-related quality of life in long-term survivors of cancer in childhood in Brazil. J Pediatr Hematol Oncol. 2008; 30(8): 563-70.
- Speechley KN, Barrera M, Shaw AK, Morrison HI, Maunsell E. Health-related quality of life among child and adolescent survivors of childhood cancer. J Clin Oncol. 2006; 24(16): 2536-43.
- Sung L, Klaassen RJ, Dix D, Pritchard S, Yanofsky R, Dzolganovski B, Almeida R, Klassen A. Identification of paediatric cancer patients with poor quality of life. Br J Cancer. 2009; 100(1): 82-8.
- Varni JW, Limbers C, Burwinkle TM. Literature review: health-related quality of life measurement in pediatric oncology: hearing the voices of the children. J Pediatr Psychol. 2007; 32(9): 1151-63.
- Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999 feb; 37(2): 126-39.
- Varricchio CG. Measurement issues in quality-of-life assessments. Oncol Nurs Forum. 2006 Jan; 33(1 Suppl): 13-21. Review.
- Yeh CH. Health-related quality of life in pediatric patients with cancer. A structural equation approach with the Roy Adaptation Model. Cancer Nurs. 2002; 25(1): 74-80.
- Zeltzer LK, Recklitis C, Buchbinder D, Zebrack B, Casillas J, Tsao JC, Lu Q, Krull K. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2009; 27(14): 2396-404.

7. A Pesquisa Clínica e os novos tratamentos Oncológicos

Evolução da Pesquisa Clínica. Monitorias da Pesquisa Clínica. Novos Tratamentos em pesquisa clínica

- ANVISA. Agência Nacional de Vigilância Sanitária. Bioequivalência. Disponível em <http://www.anvisa.gov.br/medicamentos/bioequivalencia/index.htm>. Consulta em 21 de outubro de 2006.
- ANVISA. Agência Nacional de Vigilância Sanitária. Bioequivalência: histórico. Disponível em <http://www.anvisa.gov.br/medicamentos/bioequivalencia/historico.htm>. Consulta em 21 de outubro de 2006.
- ANVISA. Agência Nacional de Vigilância Sanitária. Manual de Boas Práticas em Biodisponibilidade Bioequivalência. Vol. I. Brasília: ANVISA, 2002. 71 p.
- Botti M, Endacott R. Clinical research 5: quantitative data collection and analysis. Intensive Crit Care Nurs. 2005; 21(3): 187-93.
- Byers JF. Protecting patients during clinical research. Crit Care Nurse; 24(1): 53-9, 2004 Feb.
- Campbell T. Patient-focused care: primary responsibilities of research nurses. Br J Nurs; 7(22): 1405-9, 1998 Dec 10-1999 Jan 13.
- Carvalho V. Cuidando, pesquisando e ensinando: acerca de significados e implicações da prática da enfermagem. Rev Lat Am Enfermagem. 2004; 12(5): 806-815.
- Clarke T. Nursing research or quality improvement (QI): what standard should we expect? Aust Crit Care. 2000; 13(2): 40-2.

- Comissão Nacional de Ética em Pesquisa. Gráfico do relatório 9 anos. Disponível em <http://conselho.saude.gov.br/comissao/eticapesq.htm>. Consulta em 21 de outubro de 2006
- Comissão Nacional de Ética em Pesquisa.CEPs registrados. Disponível em <http://con-selho.saude.gov.br/comissao/eticapesq.htm>. Consulta em 21 de outubro de 2006.
- Comissão Nacional de Ética em Pesquisa.Regimento interno. Disponível em: <http://con-selho.saude.gov.br/comissao/eticapesq.htm>. Consulta em 21 de outubro de 2006.
- Comissão Técnica Nacional de Biossegurança. Cadernos de Biossegurança Legislação.Disponível em: <http://www.ctnbio.gov.br/index.php/content/view/148.html>. Consulta em 21 de outubro de 2006.
- Consulta Pública n. 04, de 19 de janeiro de 2004. Disponível em [http://www4.anvisa.gov.br/base/visadoc/CP/CP\[6217-1-0\].pdf](http://www4.anvisa.gov.br/base/visadoc/CP/CP[6217-1-0].pdf).Consulta em: 21 de outubro de 2006.
- Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, et al; Cella D+ Eastern Cooperative Oncology Group.Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. *J Clin Oncol*; 21(5): 836-42, 2003 Mar 1.
- Endacott R.Clinical research 2: Legal and ethical issues in research. *Accid Emerg Nurs*; 15(3): 166-9, 2007 Jul.
- Endacott R.Clinical Research 6: Writing and research. *Intensive Crit Care Nurs*; 21(4): 258-61, 2005 Aug.
- Endacott R, Botti M.Clinical research 3: Sample selection. *Accid Emerg Nurs*; 15(4): 234-8, 2007 Oct.
- Freitas CB, Lobo M, Hossne WS. Sistema CEPs-CONEP – 9 anos (1996 a 2005).Disponível em <http://conselho.saude.gov.br/comissao/eticapesq.htm>. Consulta em 21 de outubro de 2006.
- Gawlinski AThe power of clinical nursing research: engage clinicians, improve patients' lives, and forge a professional legacy. *Am J Crit Care*. 2008; 17(4): 315-26; quiz 327.
- Gerência de Medicamentos Novos, Pesquisa e Ensaio Clínicos. Avaliação de protocolos de estudos clínicos pela Gerência de Medicamentos Novos, Pesquisa e Ensaio Clínicos. 12 de julho de 2005. Disponível em <http://www.anvisa.gov.br/medicamentos/pesquisa/avaliacao.htm>. Consulta em 21 de outubro de 2006.
- Gerência de Medicamentos Novos, Pesquisa e Ensaio Clínicos. Dados de pesquisa clínica. Disponível em: <http://www.anvisa.gov.br/medicamentos/pesquisa/dados/index.htm>.Consult a em: 21 de outubro de 2006.
- Gerência de Medicamentos Novos, Pesquisa e Ensaio Clínicos. Instruções para submissão na Anvisa de dossiês de pesquisa clínica com medicamentos e produtos para a saúde que exijam licenciamento de importação. Disponível em <http://www.anvisa.gov.br/medicamentos/pesquisa/importa.htm>. Consulta em 21 de outubro de 2006.
- Grey M; Connolly CA.Coming together, keeping together, working together: interdisciplinary to transdisciplinary research and nursing. *Nurs Outlook*; 56(3): 102-7, 2008 May-Jun.
- Hebert JR , Brandt HM, Armstead CA, Adams SA, Steck SE.Interdisciplinary, translational, and community-based participatory research: finding a common language to improve cancer research. *Cancer Epidemiol Biomarkers Prev*; 18(4): 1213-7, 2009 Apr.
- Jutel A. Beyond evidence-based nursing: tools for practice. *J Nurs Manag*. 2008 May; 16(4):417-21.

- Ketefian S. Issues in the application of reasearch to practice. *Rev Lat Am Enfermagem*. 2001 sep.; 9(5):7-12.
- Liaschenko J, DeBruin DA. The role of nurses in ensuring the responsible conduct of clinical trials. *Minn Med*. 2003 Oct.; 86(10):35-6.
- McEwen A, Addison C. A practical guide to research for nurses and midwives. *Nurs Times*. 2006 Nov; 102(46):28-9.
- Nishioka SA, Sá PFG. A Agência Nacional de Vigilância Sanitária e a pesquisa clínica no Brasil. *Rev Assoc Med Bras*. 2006;52:60-2.
- Nishioka SA. Como é feito o registro de medicamentos novos no Brasil. *Prática Hospitalar*. 2006;VIII(45):13-17.
- Nuss SL, Hinds PS, LaFond DA. Collaborative clinical research on end-of-life care in pediatric oncology. *Semin Oncol Nurs*. 2005 May; 21(2):125-34; discussion 134-44.
- Paramonczyk A. Barriers to implementing research in clinical practice. *Can Nurse*. 2005 Mar; 101(3):12-5.
- Payne JK, Yenser SE. Use of general clinical research centers for nursing research. *Biol Res Nurs*. 2007 Oct; 9(2):142-6.
- Sheard L, Tompkins CNE, Wright NMJ, Adams CE. Non-commercial clinical trials of a medicinal product: can they survive the current process of research approvals in the UK? *J Med Ethics*. 2006;32:430-4.
- Siedlecki SL. Making a difference through research. *AORN J*. 2008 Nov; 88(5):716-29.
- Silveira CS, Zago MM. Brazilian research in oncology nursing: An integrative review. *Rev Lat Am Enfermagem*. 2006 Jul-Aug; 14(4):614-9.
- Winsett RP, Thompson DA, Gower G, Leimig R, Lloyd M, Hathaway DK. Implementing randomized assignment in a nursing clinical randomized control trial. *Prog Transplant*. 2007 Jun, 17(2):150-6.

8. Os efeitos adversos das novas drogas antineoplásicas

- Alfieri AB, Cubeddu LX. Efectos de los Antagonistas de los Receptores NK1 y de la Dexametasona sobre la inflamación neurogénica inducida por ciclofosfamida y por radiación X, en la rata. *AVFT*. 2004;23(1):61-6.
- Almeida VL, Leitão A, Reina LC, Montanari CA, Donnici CL, Lopes MT. Câncer e agentes antineoplásicos ciclo-celular específicos e ciclo-celular não específicos que interagem com o DNA: uma introdução. *Quim Nova*. 2005;28(1):118-29.
- Cerman J, Melichar B, Cermanova M, Solichova D. Management of severe infusion reactions after cetuximab. *Acta Oncol*. 2008;47(8):1609-11.
- Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. *Oncologist*. 2008 Jun;13(6):725-32. Review.
- De Lemos M. Re: Adherence to therapy with oral antineoplastic agents. *J Natl Cancer Inst*. 2002 Nov 6;94(21):1652; author reply 1652.
- Dunsford J. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. *Clin J Oncol Nurs*. 2008 Jun;12(3):405-7. Review.
- Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet*. 2000;356:1255-59.
- Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. *JAMA*. 1999;282:1453-57.
- García MA, Pascual-Teresa B. Técnicas empleadas para el estudio de la interacción entre agentes antitumorales y el DNA. *Oncologia*. 2004 Feb;27(2):33-43.

- Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? *Ann Oncol*. 2002 May;13(5):653-68.
- Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. *J Transl Med*. 2009 Jul 10;7(1):58.
- Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. *Curr Opin Oncol*. 2006 Jul;18(4):316-20. Review.
- Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFR dermatologic toxicities: US perspective. *Oncology (Williston Park)*. 2007 Oct;21(11 Suppl 5):17-21.
- Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. *JAMA* 2002; 287:2215–2220.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patient: a meta-analysis of prospective studies. *JAMA* 1998;279:1200–1205.
- Marques PC, Pierin AG. Factors that affect cancer patient compliance to oral anti-neoplastic therapy. *Acta Paul Enferm*. 2008;21(2): 323-29.
- Muriel Villoria C, Cervera Grau JM, Constela Figueras M, Sánchez Magro I, Neira Álvarez M Evaluación del tratamiento del dolor crónico en pacientes oncológicos con buprenorfina transdérmica. *Rev Soc Esp Dolor*. 2008 Jul;15(5): 291-301.
- Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician guide to terminology, documentation, and reporting. *Ann Intern Med*. 2004;140:795–801.
- Oliveira RB; Alves RJ. Agentes antineoplásicos biorredutíveis: uma nova alternativa para o tratamento de tumores sólidos. *Quim Nova*. 2002 Nov;25(6a): 976-84.
- Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. *J Natl Cancer Inst*. 2002 May 1;94(9):652-61.
- Quiñones SL, Rosero PM, Roco AA, Moreno TI, Sasso AJ, Varela FN et al. Papel de las enzimas citocromo p450 en el metabolismo de fármacos antineoplásicos: situación actual y perspectivas terapéuticas. *Rev Med Chile*. 2008 Oct;136(10):1327-35.
- Rennó Magdalena N, Barbosa GM, Zancan P, Veiga VF, Alviano Celuta S, Sola-Penna M et al. Crude ethanol extract from babassu (*Orbignya speciosa*): cytotoxicity on tumoral and non-tumoral cell lines. *An Acad Bras Ciênc*. 2008 Sep;80(3):467-76.
- Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. *CA Cancer J Clin*. 2009 Jan-Feb;59(1):56-66.
- Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. *Clin J Oncol Nurs*. 2005 Jun;9(3):332-8. Review.
- Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. *Oncologist*. 2007 Dec;12(12):1443-55. Review.

9. A Importância da notificação de reações adversas dos antineoplásicos

- Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. *Arch Intern Med*. 2007 May 28;167(10):1041-9.

- Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. *Can J Clin Pharmacol*. 2007 Winter; 14(1):e45-57.
- Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. *Br J Clin Pharmacol*. 2001 Jul; 52(1): 77-83. Review.
- Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. *Pharmacol Res*. 2006 Sep; 54(3): 226-33.
- Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. *J Clin Oncol*. 2003 Oct. 21(20): 3859-66.
- Liu BA, Knowles SR, Mittmann N, Einarson T, Shear NH. Reporting of fatal adverse drug reactions. *Can J Clin Pharmacol*. 2001; 8(2): 84-8.
- Omoti AE, Omoti CE. Toxicidad ocular de la quimioterapia sistémica anticancerosa. *Pharmacy Pract*. 2006 Jun; 4(2): 55-9.
- Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. *BMC Clin Pharmacol*. 2007 Sep 25; 7:9.
- Rodríguez IM, Valdés YC, Proveyer SD. Citostáticos: medicamentos riesgosos. *Rev Cubana Méd*. 2004 Jun; 43(2-3).
- Ruiz Gómez MJ, Souviron Rodríguez A., Martínez Morillo M. La glicoproteína-P una bomba de membrana que representa una barrera a la quimioterapia de los pacientes con cáncer. *An Med Interna*. 2002 Sep; 19(9): 49-57.
- Sabater Recolons MM, Rodríguez de Rivera Campillo ME, López López J, Chimenos Küstner E.. Manifestaciones orales secundarias al tratamiento oncológico: pautas de actuación odontológica. *Av Odontoestomatol*. 2006; 22(6): 335-42.
- Stevenson JG, Bakst CM, Zaran FK, Rybak MJ, Smolarek RT, Alexander MR. Quality improvement in the use of medications through a drug use evaluation service. *Top Hosp Pharm Manage*. 1992 Oct, 12(3): 47-56.
- Troutman WG, Doherty KM. Comparison of voluntary adverse drug reaction reports and corresponding medical records. *Am J Health Syst Pharm*. 2003 Mar, 60(6): 572-5.

10. Enfermagem e Farmácia no tratamento oncológico

Assistência do Enfermeiro em Oncologia

- Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. *Br J Cancer*. 2001 Nov 30; 85(11): 1634-9.
- Batalha de Menezes MF, Camargo TC, dos Santos Guedes MT, Lós de Alcântara LF. Cancer, poverty and human development: challenges for nursing care in oncology. *Rev Lat Am Enfermagem*. 2007 Sep-Oct; 15 Spec : 780-5.
- Beckstrand RL, Moore J, Callister L, Bond AE. Oncology nurses' perceptions of obstacles and supportive behaviors at the end of life. *Oncol Nurs Forum*. 2009 Jul; 36(4): 446-53.
- Berger AM, Berry DL, Christopher KA, Greene AL, Maliski S, Swenson KK et al. Oncology Nursing Society year 2004 research priorities survey. *Oncol Nurs Forum*. 2005 Mar 5; 32(2): 281-90.

- Boland A, Haycox A, Bagust A, Fitzsimmons L. A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. *Health Technol Assess*. 2003;7(36):1-99.
- Bouvier C. Nurse developments in neuroendocrine tumour management. *Endocr Relat Cancer*. 2003 Dec;10(4):487-8.
- Calil AM, Prado C. O ensino de oncologia na formação do enfermeiro. *Rev Bras Enferm*. 2009 Jun;62(3):467-70.
- Camargo TC, Souza IE. Care to mastectomized woman: discussing ontic aspects and the ontological dimension in nurses performance at a Cancer Hospital. *Rev Lat Am Enfermagem*. 2003 Sep-Oct;11(5):614-21.
- Cameron GT, Geana MV. Functional foods: delivering information to the oncology nurse. *J Nutr*. 2005 May;135(5):1253-5.
- Carvalho V. Caring, researching and teaching: meanings and implications of nursing practice. *Rev Lat Am Enfermagem*. 2004 Sep-Oct;12(5):806-15.
- Cooley ME, Sipples RL, Murphy M, Sarna L. Smoking cessation and lung cancer: oncology nurses can make a difference. *Semin Oncol Nurs*. 2008 Feb;24(1):16-26.
- Dauer LT, Kelvin JF, Horan CL, St Germain J. Evaluating the effectiveness of a radiation safety training intervention for oncology nurses: a pretest-intervention-posttest study. *BMC Med Educ*. 2006 Jun 8;6:32.
- Faria DA, Maia EM. Nursing professionals' anxiety and feelings in terminal situations in oncology. *Rev Lat Am Enfermagem*. 2007 Nov-Dec;15(6):1131-7.
- Ferreira NM. A difícil convivência com o câncer: um estudo das emoções na enfermagem oncológica. *Rev Esc Enf USP* 1996 Ago;30(2):229-53.
- Ferrell BR, Virani R, Smith S, Juarez G; National Cancer Policy Board, Institute of Medicine. The role of oncology nursing to ensure quality care for cancer survivors: a report commissioned by the National Cancer Policy Board and Institute of Medicine. *Oncol Nurs Forum*. 2003 Jan-Feb;30(1):E1-E11.
- Frazier SR. Nursing perspectives on patient management during chronic therapy for relapsed ovarian cancer. *Cancer Control*. 2001 Nov-Dec;8(6 Suppl 1):19-21.
- Gaff C, Aittomäki K, Williamson R. Oncology nurse training in cancer genetics. *J Med Genet*. 2001 Oct;38(10):691-5.
- Giesler RB, Given B, Given CW, Rawl S, Monahan P, Burns D et al. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention. *Cancer*. 2005 Aug 15;104(4):752-62.
- Grant M, Mooney K, Rutledge D, Gerard S, Eaton L. Cancer nursing research short course: long-term follow-up of participants, 1984-1998. *Oncol Nurs Forum*. 2004 Mar-Apr;31(2):E32-8.
- Grenon NN, Chan J. Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. *Clin J Oncol Nurs*. 2009 Jun;13(3):285-96.
- Hann DM, Baker F, Denniston MM, Winter K. Oncology professionals' views of complementary therapies: a survey of physicians, nurses, and social workers. *Cancer Control*. 2004 Nov-Dec;11(6):404-10.
- Hinds PS, Baggott C, DeSwarte-Wallace J, Dodd M, Haase J, Hockenberry M et al. Online exclusive: functional integration of nursing research into a pediatric oncology cooperative group: finding common ground. *Oncol Nurs Forum*. 2003 Nov-Dec;30(6):E121-6.
- Honea NJ, Brintnall R, Given B, Sherwood P, Colao DB, Somers SC et al. Putting evidence into practice: nursing assessment and interventions to reduce family caregiver strain and burden. *Clin J Oncol Nurs*. 2008 Jun;12(3):507-16.
- Hoon EA, Newbury JW, Chapman P, Price J. Education to improve cancer care in rural South Australia. *Rural Remote Health*. 2009 Apr-Jun;9(2):1147.

- King CR, Hinds P, Dow KH, Schum L, Lee C. The nurse's relationship-based perceptions of patient quality of life. *Oncol Nurs Forum*. 2002 Nov-Dec;29(10):E118-26.
- Knobf MT, Juarez G, Lee SY, Sun V, Sun Y, Haozous E. Challenges and strategies in recruitment of ethnically diverse populations for cancer nursing research. *Oncol Nurs Forum*. 2007 Nov;34(6):1187-94.
- Long JM. Treatment approaches and nursing applications for non-Hodgkin lymphoma. *Clin J Oncol Nurs*. 2007 Feb;11(1 Suppl):13-21.
- Menezes MF, Camargo TC. Cancer-related fatigue as a thematic issue in oncology nursing. *Rev Lat Am Enfermagem*. 2006 May-Jun;14(3):442-7.
- Miaskowski C, Shockney L, Chlebowski RT. Adherence to oral endocrine therapy for breast cancer: a nursing perspective. *Clin J Oncol Nurs*. 2008 Apr;12(2):213-21.
- Myers JS, Teel C. Oncology nurses' awareness of cognitive impairment secondary to chemotherapy. *Clin J Oncol Nurs*. 2008 Oct;12(5):725-9.
- O'Mara A, Bauer-Wu S, Berry D, Lillington L. A needs assessment of oncology nurses' perceptions of National Cancer Institute-supported clinical trial networks. *Oncol Nurs Forum*. 2007 Mar;34(2):E23-7.
- Oncology Nursing Society, Geriatric Oncology Consortium. Oncology Nursing Society and Geriatric Oncology Consortium joint position on cancer care for older adults. *Oncol Nurs Forum*. 2007 May;34(3):623-4.
- Oncology Nursing Society. Nurses' responsibility to patients requesting assistance in hastening death. *Oncol Nurs Forum*. 2007 Jul;34(4):763-4.
- Oncology Nursing Society. Psychosocial services for patients with cancer. *Oncol Nurs Forum*. 2008 May;35(3):337.
- Oncology Nursing Society. The impact of the national nursing shortage on quality cancer care. *Oncol Nurs Forum*. 2007 Nov;34(6):1095.
- Oncology Nursing Society; Association of Oncology Social Work. Oncology Nursing Society and Association of Oncology Social Work joint position on palliative and end-of-life care. *Oncol Nurs Forum*. 2007 Nov;34(6):1097-8.
- Oztekin DS, Ucuzal M, Oztekin I, İşsever H. Nursing students' willingness to use complementary and alternative therapies for cancer patients: Istanbul survey. *Tohoku J Exp Med*. 2007 Jan;211(1):49-61.
- Razavi D, Delvaux N, Marchal S, Durieux JF, Farvacques C, Dubus L et al. Does training increase the use of more emotionally laden words by nurses when talking with cancer patients? A randomised study. *Br J Cancer*. 2002 Jul 1;87(1):1-7.
- Rivera HR. Depression symptoms in cancer caregivers. *Clin J Oncol Nurs*. 2009 Apr;13(2):195-202.
- Rodrigues AB, Chaves EC. Stressing factors and coping strategies used by oncology nurses. *Rev Lat Am Enfermagem*. 2008 Jan-Feb;16(1):24-8.
- Schaal AD, Skalla KA, Mulrooney TJ, Stearns D, Smith EM. Building a collaboration of hematology-oncology advanced practice nurses. Part II: outcomes. *Oncol Nurs Forum*. 2008 Nov;35(6):875-8.
- Schapira L, Gordon-Rowe L, Martignetti R, Washington D, Bartholomay M, Greenberg D et al. Racism in the chemotherapy infusion unit: a nurse's story. *Oncologist*. 2008 Nov;13(11):1177-80.
- Sehlen S, Vordermark D, Schäfer C, Herschbach P, Bayerl A, Pigorsch S et al. Job stress and job satisfaction of physicians, radiographers, nurses and physicists working in radiotherapy: a multicenter analysis by the DEGRO Quality of Life Work Group. *Radiat Oncol*. 2009 Feb 6;4:6.
- Silveira CS, Zago MM. Brazilian research in oncology nursing: an integrative review. *Rev Lat Am Enfermagem*. 2006 Jul-Aug;14(4):614-9.
- Smith EL, Skosey C, Armer J, Berg D, Cirrincione C, Henggeler M. The cancer and leukemia group B oncology nursing committee (1983-2006): a history of passion, commitment, challenge, and accomplishment. *Clin Cancer Res*. 2006 Jun 1;12(11 Pt 2):3638s-41s.

- Spigelman A. Breast cancer clinic led by a nurse practitioner. *J R Soc Med.* 1997 Sep;90(9):525-6.
- Stoll BA. Specialist breast and ovarian cancer clinics should be staffed by oncologist nurses. *BMJ.* 1996 Apr 6;312(7035):913.
- Tariman JD, Estrella SM. The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing. *Oncol Nurs Forum.* 2005 Nov 3;32(6):E127-38.

Atenção Farmacêutica em Oncologia

- Arroyo Conde C, Aquerreta I, Ortega Eslava A, Goñi Zamarbide O, Giráldez Deiró J. Clinical and economic impact of the pharmacy resident incorporation into the healthcare team. *Farm Hosp.* 2006 Sep-Oct;30(5):284-90.
- Brazier AS, Balneaves LG, Seely D, Stephen JE, Suryaprakash N, Taylor-Brown JW. Integrative practices of Canadian oncology health professionals. *Curr Oncol.* 2008 Aug;15 Suppl 2:s110.es87-91.
- Cavero Rodrigo E, Climente Martí M, Navarro Fontestad MC, Jiménez Torres NV. Quality assessment of two pharmaceutical care models for onco-haematological patients. *Farm Hosp.* 2007 Jul-Aug;31(4):231-7.
- Hayakawa T, Yamanouchi K, Hirohata T, Totsu S, Makino A, Sato H et al. Establishment of pharmaceutical management for patient care during lung cancer chemotherapy and its quantitative evaluation. *Yakugaku Zasshi.* 2005 May;125(5):405-16.
- Kachroo S. Pharmacists should assume a larger role in overcoming the racial/ethnic barriers to breast cancer screening. *J Manag Care Pharm.* 2006 Jun;12(5):406-7.
- Lohrisch D, Ryan MR, Rosenbluth SA. Long-term effects of a cancer awareness program for community pharmacists. *Am J Public Health.* 1978 Dec;68(12):1217-8.
- Mayer JA, Eckhardt L, Stepanski BM, Sallis JF, Elder JP, Slymen DJ et al. Promoting skin cancer prevention counseling by pharmacists. *Am J Public Health.* 1998 Jul;88(7):1096-9.
- McGarry RC, McGarry P. Please pass the strychnine: the art of Victorian pharmacy. *CMAJ.* 1999 Dec 14;161(12):1556-8.
- McIntosh J, Sturpe DA, Khanna N. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. *J Am Pharm Assoc.* 2008 Jan-Feb;48(1):e1-13.
- Peña J, Santos B, Briones E, Corbacho B, Fernández Feijóo A, Expósito J. Chemotherapy registry quality in Andalusian hospital pharmacy departments. *Farm Hosp.* 2006 Nov-Dec;30(6):370-3.
- Ramos FM, Arbesú MA, Sedeño AC, Fernández MS. El farmacéutico como educador sanitario en pacientes que reciben poliquimioterapia. *Rev Cubana.* 2006 Ago; 40(2).
- Thompson, CA. Oncology practices recruit pharmacists for efficiency, savings. *Am J Health Syst Pharm.* 2006;63:1774-75.
- Turner CJ, Ellis S, Giles J, Maffeo C, Hansen L, Saseen JJ, et al. A strategy to develop advanced pharmacy practice experiences. *Am J Pharm Educ.* 2007 Jun, 71(3):46.
- Yamamura S, Takehira R, Kawada K, Katayama S, Nishizawa K, Hirano M et al. Structural equation modeling of qualification of pharmacists to improve subjected quality of life in cancer patients. *J Pharm Pharm Sci.* 2005 Oct 4;8(3):544-51.

O Enfermeiro e a administração de drogas antineoplásicas. O Farmacêutico e a manipulação de drogas antineoplásicas

- Bond CM, Bradley C. Over the counter drugs. The interface between the community pharmacist and patients. *BMJ*. 1996 Mar 23; 312(7033):758-60.
- Cote DD, Torchia MG. Robotic system for i.v. antineoplastic drug preparation: description and preliminary evaluation under simulated conditions. *Am J Hosp Pharm*. 1989 Nov; 46(11):2286-93.
- Curtiss FR, Fry RN, Avey SG. Framework for pharmacy services quality improvement--a bridge to cross the quality chasm. Part I. The opportunity and the tool. *J Manag Care Pharm*. 2004 Jan-Feb; 10(1):60-78. Review.
- Da Fonseca SM, Gutiérrez MG, Adami NP. Avaliação da satisfação de pacientes oncológicos com atendimento recebido durante o tratamento antineoplásico ambulatorial. *Rev Bras Enferm*. 2006 Out; 59(5):656-60.
- Dear R, Wilcken N, Shannon J. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments. *Aust Fam Physician*. 2008 Jan-Feb; 37(1-2):45-9. Review.
- Fransman W, Peelen S, Hilhorst S, Roeleveld N, Heederik D, Kromhout H. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. *Ann Occup Hyg*. 2007 Apr; 51(3):231-9.
- Gerber DE. Targeted therapies: a new generation of cancer treatments. *Am Fam Physician*. 2008 Feb 1; 77(3):311-9. Review.
- Hammond RW, Schwartz AH, Campbell MJ, Remington TL, Chuck S, Blair MM, Vassey AM, Rospond RM, Herner SJ, Webb CE; American College of Clinical Pharmacy. Collaborative drug therapy management by pharmacists--2003. *Pharmacotherapy*. 2003 Sep; 23(9):1210-25.
- Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. *Pharmacotherapy*. 2004 Nov; 24(11):1491-8. Review.
- Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. *Mutagenesis*. 2007 Nov; 22(6):395-401.
- Rocha FR, Marziale MHP, Robazzi ML. Perigos potenciais a que estão expostos os trabalhadores de enfermagem na manipulação de quimioterápicos antineoplásicos: conhecê-los para preveni-los. *Rev Lat Am Enfermagem*. 2004; 12(3):511-517.
- Scott SA, Schrott DB, Loesch GA. Pharmacy program for improved handling of antineoplastic agents. *Am J Hosp Pharm*. 1983 Jul; 40(7):1179-82.
- Xelegati R, Robazzi Maria LCC, Marziale MHP, Haas VJ. Chemical occupational risks identified by nurses in a hospital environment. *Rev Lat Am Enfermagem*. 2006 Apr; 14(2):214-19.
- Ziegler E, Mason HJ, Baxter PJ. Occupational exposure to cytotoxic drugs in two UK oncology wards. *Occup Environ Med*. 2002 Sep; 59(9):608-12.

11. A Enfermagem e a Farmácia Oncológica do Futuro

O Enfermeiro no futuro do tratamento oncológico

- Aguiar RV, Cassiani SH. Development and evaluation of a virtual learning environment in professional nursing courses. *Rev Lat Am Enfermagem*. 2007; 15(6): 1086-91.
- Alexandre NM. Ergonomic aspects of hospital environment and equipment. *Rev Lat Am Enfermagem*. 1998 Oct; 6(4):103-9.
- Arone EM, Cunha IC. Avaliação tecnológica como competência do enfermeiro: reflexões e pressupostos no cenário da ciência e tecnologia. *Rev Bras Enferm*. 2006; 59(4):569-72.
- Arone EM, Cunha IC. Tecnologia e humanização: desafios gerenciados pelo enfermeiro em prol da integralidade da assistência. *Rev Bras Enferm*. 2007; 60(6):721-23.

- Chaves LC. Recapagem de agulhas pelos componentes da equipe de enfermagem: riscos e prevenção. *Arq Med ABC*. 2002;26(3):39-43.
- Cogo AP, Pedro ER, Silveira DT, Silva, AS, Alves, RK, Catalan VM. Development and use of digital educative objects in nursing teaching. *Rev Lat Am Enfermagem*. 2007;15(4): 699-701.
- Demark-Wahnefried W, Jones LW. Promoting a healthy lifestyle among cancer survivors. *Hematol Oncol Clin North Am*. 2008 Apr;22(2):319-42.
- Doorenbos AZ, Berger AM, Brohard-Holbert C, Eaton L, Kozachik S, LoBiondo-Wood G et al. Oncology nursing society putting evidence into practice resources: where are we now and what is next? *Clin J Oncol Nurs*. 2008 Dec;12(6):965-70.
- Doorenbos AZ, Berger AM, Brohard-Holbert C, Eaton L, Kozachik S, LoBiondo-Wood G et al. 2008 ONS research priorities survey. *Oncol Nurs Forum*. 2008 Nov;35(6):E100-7.
- Eiser C, Eiser JR, Stride CB. Quality of life in children newly diagnosed with cancer and their mothers. *Health Qual Life Outcomes*. 2005;3:29.
- Hegarty J, Walsh E, Condon C, Sweeney J. The undergraduate education of nurses: looking to the future. *Int J Nurs Educ Scholarsh*. 2009;6(1):Article17.
- Kawabata Y, Nakagawa A, Uchikoshi H, Tamiya Y. The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients. *Yakugaku Zasshi*. 2009 Mar;129(3):359-64.
- Lourenço KG, Castilho V. Classificação ABC dos materiais: uma ferramenta gerencial de custos em enfermagem. *Rev Bras Enferm*. 2006;59(1):52-5.
- Lowrey KM. Legal and ethical issues in cancer genetics nursing. *Semin Oncol Nurs*. 2004 Aug; 20(3):203-8.
- Marin HF, Cunha ICKO. Perspectivas atuais da Informática em Enfermagem. *Rev Bras Enferm*. 2006 Jun;59(3):354-57.
- Martins JJ, Nascimento ER. A tecnologia e a organização do trabalho da Enfermagem em UTI. *Arq Catarin Med*. 2005;34(4):23-7.
- Rossi FR, Lima MA. Welcoming: soft technology in nurse's management processes. *Rev Bras Enferm*. 2005;58(3):305-10.
- Tipple AF, de Souza TR, Bezerra AL, Munari DB. The worker with no training in nursing in a center of materials and sterilization: a challenge to the nurse. *Rev Esc Enferm USP*. 2005 Jun;39(2):173-80.
- Vanderbeek J, Carson A, Troy D. Evolution of a collaborative model between nursing and computer science faculty and a community service organization to develop an information system. *Comput Inform Nurs*. 2008;26(4):215-20.

O Farmacêutico no futuro do tratamento oncológico

- AMCP Task Force on Drug Payment Methodologies. AMCP Guide to Pharmaceutical Payment Methods. *J Manag Care Pharm*. 2007 Oct;13(8 Suppl C):S1-39.
- Byrd GD. Can the profession of pharmacy serve as a model for health informationist professionals? *J Med Libr Assoc*. 2002 Jan;90(1):68-75. Review.
- Deininger MW. Nilotinib. *Clin Cancer Res*. 2008 Jul 1;14(13):4027-31.
- Dennis RV, Pinto DM. Pharmacoeconomy. *Acta Med Colomb*. 2006;31(2):53-5.
- Dhalla I, Laupacis A. Moving from opacity to transparency in pharmaceutical policy. *CMAJ*. 2008 Feb;178(4): 428-31.
- Fischer PM. The use of CDK inhibitors in oncology: a pharmaceutical perspective. *Cell Cycle*. 2004 Jun;3(6):742-6.

- Flowers L, Wick J, Figg WD Sr, McClelland RH, Shiber M, Britton JE, et al. U.S. Public Health Service Commissioned Corps pharmacists: making a difference in advancing the nation's health. *J Am Pharm Assoc* (2003). 2009 May-Jun; 49(3): 446-52.
- Gastelurrutia MA, Benrimoj SI, Castrillon CC, de Amezua MJ, Fernandez-Llimos F, Faus MJ. Facilitators for practice change in Spanish community pharmacy. *Pharm World Sci*. 2009 Feb; 31(1): 32-9.
- Gondim AP, Falcao CB. Evaluation of Brazilian online pharmacies. *Rev Saude Publica*. 2007 Apr; 41(2): 297-300.
- Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm*. 1990 Mar; 47(3): 533-43.
- Herrera MC. Farmacoeconomía: eficiencia y uso racional de los medicamentos. *Rev Bras Cienc Farm*. 2004 Dec; 40(4): 445-53.
- Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B et al. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. *Arch Dermatol*. 2008 Mar; 144(3): 361-4.
- Knapp DA. Pharmacy practice in 2040. *Am J Hosp Pharm*. 1992 Oct; 49(10): 2457-61.
- Lopez-Casasnovas G. Regulation, innovation, and improvement of health care: the pharmaceutical sector. *Gac Sanit*. 2008; 22(1): 52-7.
- Matsoso MP. Future vision and challenges for hospital pharmacy. *Am J Health Syst Pharm*. 2009 Mar 1; 66(5 Suppl 3): S9-12.
- Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, et al. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. *J Clin Oncol*. 2009 Jul 6.
- Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. *Nat Rev Cancer*. 2005 Apr; 5(4): 285-96.
- Oliveira DR, Varela ND. La investigación cualitativa en farmacia: aplicación en la Atención Farmacéutica. *Rev. Bras. Cienc. Farm*. 2008; 44(4): 763-72 .
- Osorio-de-Castro, CG. Farmacêutico: ser profissional de saúde e cidadão exige responsabilização. *Ciênc saúde coletiva*. 2008; 13(suppl.): 572-75.
- Pereira RL, Freitas O. A evolução da Atenção Farmacéutica e a perspectiva para o Brasil. *Rev Bras Cienc Farm*. 2008 Dec; 44(4): 601-12.
- Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J et al. Translating pharmacogenomics: challenges on the road to the clinic. *Plos Med*. Aug 2007; 4(8): e209.
- Vieira FS. Possibilidades de contribuição do farmacêutico para a promoção da saúde. *Ciênc Saúde Coletiva* 2007; 12(1): 213-20.
- Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. *Br J Cancer*. 2006 Jun; 94(12): 1765-9.

SITES RELACIONADOS

Nacionais

Assistência Farmacêutica – www.assistenciafarmaceutica.org.br

Associação Brasileira de Farmacêuticos Associação Médica Brasileira – www.abf.org.br

Biblioteca Virtual de Enfermagem - www.bve.org.br/portal

BIREME – www.bireme.br

Câncer de Mama – www.cancerdemama.org.br

Centro de Estudos e Pesquisas Oncologias de Minas Gerais – CEOMG – www.ceomg.com.br

Centro de Quimioterapia Antineoplásica e Imunoterapia – CQAI – www.cqai.com.br

Cibersaude – www.cibersaude.com.br

Conselho Federal de Enfermagem – www.portalcofen.com.br
 Conselho Federal de Farmácia – www.cff.org.br
 Enfermagem - www.enfermagem.org
 Enfermagem Oncológica – www.hcanc.org.br/smaux/enf/enf1.htm
 Enfermagem Virtual - www.enfermagemvirtual.com.br
 Fundação Nacional de Saúde – www.fns.ms.gov.br
 Grupo Multidisciplinar em Oncologia – www.unifesp.br/centros/gmo/enferm.htm
 Hospital do Câncer A. C. Camargo – www.hcanc.org.br
 Instituto Brasileiro de Controle do Câncer – www.ibcc.org.br
 Instituto Nacional do Câncer – INCA – www.inca.gov.br
 Organização Nacional de Acreditação - <http://www.ona.org.br>
 SOBRAFO – Sociedade Brasileira de Farmacêuticos Oncológicos -
<http://www.sobrafo.org.br>.

Internacionais

American Academy of Ambulatory Care Nursing – www.aaacn.inurse.com
 American Cancer Society – www.cancer.org
 American Society of Clinical Oncology – www.asco.org
 American Society of Health-System Pharmacists – www.ashp.com
 Association of Pediatric Oncology Nurses – www.apon.org
 Canadian Cancer Association – www.can-nurses.ca
 Cancer Nursing - www.cancernursing.org
 Cancer Care – www.cancercares.org
 Cancer Links – www.cancerlinks.org
 Cancer Research and Prevention Foundation – www.preventcancer.org
 Cochrane - www.cochrane.org
 Drug International Association – www.diahome.gov
 European Journal of Oncology Nursing -
<http://www.sciencedirect.com/science/journal/13649825>
 European Society of Clinical Pharmacy - www.escp.nl
 Food and Drug Administration – FDA – www.fda.gov
 International Agency for Research on Cancer – www.iarc.fr
 International Society for Nurses in Cancer Care – www.isncc.org
 M. D. Anderson Cancer Center – www.mdanderson.org
 Moffitt Cancer Center – www.moffitt.usf.edu
 National Cancer Center Network – NCC – www.nccn.org
 National Cancer Institute – NCI – www.cancer.gov
 NCI Cancer Trials – www.cancer.gov/clinicaltrials
 NursingWorld - American Nurses Association – www.nursingworld.org
 OFIL - Organização de Farmacêuticos Ibero Latinos Americanos - www.ofil.org.br
 Oncology Nursing Society – www.ons.org
 PDA-Parenteral Drug Association - www.pda.gov
 Pharmacist – www.pharmacist.com
 Seminars in Oncology Nursing - www.nursingoncology.com/search/results
 The Alliance – Nursing Organizations Alliance – www.nursing-alliance.org
 The American Society of Clinical Oncology – www.asco.org
 World Oncology Network – www.worldoncology.net

(*) Bibliografia pesquisada pelas bibliotecárias do CQAI: Amanda Damasceno de Souza CRB6-2427, e Isabela Monteiro Braga - CRB6-2693.